A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
A Phase 2/3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy, Safety and Tolerability of BHV-7000 in Subjects With Refractory Focal Onset Epilepsy
Biohaven Therapeutics Ltd.
390 participants
Mar 14, 2024
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
BHV-7000 25 mg. Participants will take blinded investigational product (IP) once daily
BHV-7000 50 mg. Participants will take blinded investigational product (IP) once daily
Matching placebo taken once daily
BHV-7000 75 mg. Participants willtake blinded investigational product(IP) once daily
Matching placebo taken once daily
Locations(124)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06132893